A free prostate-specific antigen (PSA) test is used to confirm test results from a PSA test. A PSA test is used to see if you may have prostate cancer. The test measures the level of PSA in your blood.

A doctor may use a free PSA test to help make a diagnosis when total PSA levels are high

0 ng/ml to 4 ng/ml

The Prostate-Specific Antigen (Free) test, often abbreviated as FPSA or fPSA, measures the level of free prostate-specific antigen in the blood. Here's how to interpret the results of an FPSA test: Normal Range: The normal range for FPSA levels can vary depending on the laboratory and the specific assay method used for testing. Generally, FPSA levels are expressed as a percentage of total PSA (TPSA). The normal ratio of FPSA to TPSA is typically greater than 15%. Interpretation: Normal FPSA Level: A normal FPSA level, particularly when the ratio of FPSA to TPSA is greater than 15%, suggests that most of the PSA in the blood is in the free form. This is typical in men with benign prostatic hyperplasia (BPH) or other non-cancerous conditions of the prostate. Low FPSA Level or Decreased Ratio: A decreased ratio of FPSA to TPSA may indicate a higher likelihood of prostate cancer. In prostate cancer, there is often an increase in total PSA levels, leading to a decrease in the proportion of free PSA compared to complexed PSA (cPSA). A low FPSA level or decreased ratio may prompt further evaluation for prostate cancer, such as prostate biopsy. High FPSA Level or Increased Ratio: Conversely, an increased ratio of FPSA to TPSA may suggest a lower risk of prostate cancer. However, other factors such as prostate size, age, and presence of inflammation or infection can also influence FPSA levels, so interpretation should be done cautiously. Clinical Correlation: Interpretation of FPSA test results should be done in conjunction with clinical assessment, including consideration of the patient's medical history, symptoms, digital rectal examination findings, and other risk factors for prostate cancer. Additional tests or evaluations, such as imaging studies or prostate biopsy, may be necessary to confirm or rule out prostate cancer in individuals with abnormal FPSA levels or other concerning findings. Screening and Monitoring: FPSA testing is often used in conjunction with total PSA (TPSA) testing as part of prostate cancer screening and monitoring. While FPSA testing can provide additional information to help differentiate between benign prostatic conditions and prostate cancer, it is not a definitive diagnostic test for prostate cancer on its own. Diagnosis of prostate cancer typically requires further evaluation, such as prostate biopsy. Interpretation of FPSA test results should be performed by a healthcare provider experienced in urology or oncology. It's important to consider the patient's overall clinical picture, including risk factors for prostate cancer, to determine the appropriate diagnostic and management plan.

Blood